Phase Ib/II Clinical Study of SHR-8068 Combined Anti-tumor Drugs in the Treatment of Advanced Renal Cell Carcinom
A phase 1/2 trial of SHR-8068 in renal cell carcinoma, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., now recruiting.
Overview
Phase Ib/II Clinical Study of SHR-8068 Combined Anti-tumor Drugs in the Treatment of Advanced Renal Cell Carcinom is a phase 1/2 interventional study registered as NCT07239596 by Suzhou Suncadia Biopharmaceuticals Co., Ltd., with 92 participants planned, started 2026-01-06 and due to reach its primary completion in 2030-12. Interventions recorded: SHR-8068；Adebrelimab ；Bevacizumab, SHR-8068 ; SHR-4610. Conditions listed: Advanced Renal Cell Carcinoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Clinical Study of Adebrelimab in Combination With SHR-8068 and Chemoradiotherapy as Perioperative Therapy for Locally Advanced Rectal Cancer
Shares SHR-8068, Jiangsu Hengrui Pharmaceuticals.
- TrialA Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC)
Shares SHR-8068, Jiangsu Hengrui Pharmaceuticals.
- TrialA Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer
Shares SHR-8068, Jiangsu Hengrui Pharmaceuticals.
- TrialA Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ Cancer
Shares SHR-8068, Jiangsu Hengrui Pharmaceuticals.
- TrialA Clinical Study of SHR-A1811 in the Treatment of HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer
Shares SHR-8068, Jiangsu Hengrui Pharmaceuticals.
- TrialA Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC
Shares SHR-8068, Jiangsu Hengrui Pharmaceuticals.
- TrialA Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carcinoma
Shares SHR-8068, Jiangsu Hengrui Pharmaceuticals.
- TrialA Trial of SHR-4849 Combined With Other Antitumor Drugs in Patients With Malignant Solid Tumors
Shares SHR-8068, Jiangsu Hengrui Pharmaceuticals.